The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Vascular Solutions met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share grew significantly.
Margins expanded across the board.
Vascular Solutions notched revenue of $25.3 million. The five analysts polled by S&P Capital IQ wanted to see net sales of $25.6 million on the same basis. GAAP reported sales were 15% higher than the prior-year quarter's $22.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.22. The five earnings estimates compiled by S&P Capital IQ forecast $0.17 per share. GAAP EPS of $0.18 for Q4 were 38% higher than the prior-year quarter's $0.13 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 67.2%, 150 basis points better than the prior-year quarter. Operating margin was 18.5%, 290 basis points better than the prior-year quarter. Net margin was 12.1%, 230 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $26.3 million. On the bottom line, the average EPS estimate is $0.16.
Next year's average estimate for revenue is $108.7 million. The average EPS estimate is $0.68.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 95 members out of 107 rating the stock outperform, and 12 members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 21 give Vascular Solutions a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vascular Solutions is outperform, with an average price target of $17.10.
Looking for alternatives to Vascular Solutions? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Vascular Solutions to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.